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We have previously reported a functional role associated with hepatitis C virus (HCV) E1 glycoprotein using vesicular stomatitis virus
(VSV)/HCV pseudotype. In this study, we have investigated the role of glycosylation upon intracellular transport of chimeric E1-G, and in
infectivity of the pseudotyped virus. Interestingly, surface expressed E1-G exhibited sensitivity to Endoglycosidase H (Endo H) treatment,
which was similar to full-length E1, suggesting that additional complex oligosaccharides were not added while E1-G was in transit from the
endoplasmic reticulum (ER) to the mammalian cell surface. As a next step, each of the four potential N-linked glycosylation sites located at
amino acid position 196, 209, 234, or 305 of the E1 ectodomain were mutated separately (asparagine! glutamine), or in some combination.
FACS analysis suggested that mutation(s) of the glycosylation sites affect the translocation of E1-G to the cell surface to different extents,
with no single site being particularly essential. VSV pseudotype virus generated from glycosylation mutants exhibited a decrease in titer with
an increasing number of mutations at the glycosylation sites on chimeric E1-G. In a separate experiment, N-glycosidase F treatment of
pseudotype generated from the already synthesized E1-G or its mutants decreased virus titer by approximately 35%, and the neutralization
activity of patient sera was not significantly altered with N-glycosidase F-treated pseudotype virus. Taken together, our results suggested that
E1-G does not add complex sugar moieties during transport to the cell surface and retain the glycosylation profile of its parental E1 sequence.
Additionally, the removal of glycans from the E1-G reduced, but does not completely impair, virus infectivity.
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IntroductionHepatitis C virus (HCV) causes a spectrum of disease
ranging from an asymptomatic carrier state to end-stage
liver disease, which includes cirrhosis and hepatocellular
carcinoma (DiBisceglie et al., 1998; Hayashi et al., 1999;
Jeffers, 2000; Saito et al., 1990). The study of HCV is
challenging due to its inefficient replication in cell culture
and the lack of a small animal model. HCV genome is a
single positive-strand RNA that encodes a polyprotein of
approximately 3000 amino acids. The polyprotein is cleaved
by both host and viral proteases to generate at least 10
different proteins. The structural proteins of HCV (core, E1,0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: rayr@slu.edu (R. Ray).and E2/p7) are processed by host peptidase present in the
endoplasmic reticulum (ER) lumen. Immunoelectron micro-
scopic study suggests that the E1 and E2 glycoproteins are
located on the virus envelope (Kaito et al., 1994), and they
most likely facilitate virus entry by interacting with host cell
surface. During HCV protein synthesis, E1 glycoprotein
(approximately 32 kDa) localizes in the cytoplasm and is
retained in the ER (Hijikata et al., 1991; Ralston et al., 1993;
Spaete et al., 1992). E1 glycosylation is sensitive to Endo H
digestion, further suggesting that this viral glycoprotein is
not modified by Golgi (Lanford et al., 1993). The E1 protein
consists of 191 amino acids occupying positions between
amino acid residues 192–383 in the HCV polyprotein. E1
contains five conserved potential glycosylation sites at
amino acid positions 196, 209, 234, 305, and 325; however,
position 325 is not efficiently glycosylated (Meunier et al.,
1999). This viral protein has two hydrophobic domains,
located at the internal position between amino acid residues
A. Beyene et al. / Virology 324 (2004) 273–285274261 and 291, and at the C-terminal region between amino
acid residues 329 and 383 (Takamizawa et al., 1991). The
C-terminal domain has the retention signal in the ER
membrane, while the internal domain is involved in binding
with capsid protein (Cocquerel et al., 1999; Ma et al., 2002),
and may have membrane-active properties (Ciccaglione et
al., 2001).
N-linked glycosylation of viral polypeptides are important
for a variety of biological and immunological functions
(Hansen et al., 1990; Helenius, 1994; Varki, 1993). Glyco-
sylation of proteins also help in the formation and mainte-
nance of native protein conformation, and protect the protein
from proteolytic degradation (Ellgaard et al., 1999; Means
and Desrosiers, 2000; Trombetta and Helenius, 1998). How-
ever, the blocking of N-linked glycosylation sites has sug-
gested that some proteins are not affected, whereas others are
degraded or fail to reach their correct cellular destination
(Machamer et al., 1985; Olden et al., 1982; Sodora et al.,
1989). Little is known about the relative contribution of the
protein and carbohydrate to the various activities of HCV
envelope glycoproteins. We have previously shown that
concanavalin A plant lectin interacts with pseudotype virus
expressing the ectodomain of HCV E1 glycoprotein, while
mannose-binding protein (a C-type mammalian lectin) did
not (Meyer et al., 2000). Recent studies from other inves-
tigators suggest that pseudotype expressing chimeric E1
glycoprotein binds efficiently to DC-SIGN and DC-SIGNR
expressed on cells, but not to other C-type lectins (Lozach et
al., 2003; Pohlmann et al., 2003).
The lack of an efficient in vitro system for the propagation
of HCV makes it difficult to identify cell surface attachment
factors or virus receptors. We have developed a pseudotype
virus system to understand the role of HCV envelope
glycoproteins in the initiation of viral infection (Lagging et
al., 1998). A temperature-sensitive mutant of vesicular
stomatitis virus (VSVts045) was used as the core virus for
generation of pseudotype. This VSVts045 has a single amino
acid mutation on the surface glycoprotein G. At permissive
temperature (32 jC), VSVts045 assemble normally and
display infectivity. In contrast, when VSVts045 is grown at
a nonpermissive temperature (40.5 jC), the G glycoprotein
undergoes a conformational change, which leads to its
retention in the endoplasmic reticulum (Doms et al., 1993).Fig. 1. (Panel A) E1-G chimeric glycoprotein translocates onto cell surface thro
transfected with E1-G plasmid DNA. Cells were stained after 18 h with a murine
anti-giantin antibody as a Golgi marker. A secondary antibody to murine Ig-FITC
were merged digitally for fine comparison. (Panel B) E1-G chimeric protein is
transfected with plasmid DNA encoding chimeric E1-G, full-length E1, or pcDNA
with 35S-cysteine/methionine for 2 h. Cell lysates were immunoprecipitated with a
were analyzed by SDS-12% PAGE under reducing conditions. Arrows on the le
(marked by *) E1-G or E1. The positions of protein molecular weight markers (I
analysis for Endo H sensitivity of chimeric E1-G. HeLa cells were infected with re
G, full-length E1, or pcDNA3 vector as a negative control. After 18 h of trans
Biologicals). Immunoprecipitates were digested with Endo H or left untreated
nitrocellulose membrane, and E1 protein was detected using MAb A4, followed b
was visualized by chemiluminescence. Arrows on the left indicate the positions of
E1. The positions of protein molecular weight markers (Invitrogen) are indicatedAs a result, VSVts045 is unable to assemble its spike
glycoprotein G for virus morphogenesis. We exploited this
unique property of VSVts045 to generate VSV/HCV pseu-
dotype virus. Pseudotype expressing chimeric E1-G or E2-G
glycoprotein displayed infectivity at permissive temperature
(32 jC), suggesting an individual role for each in cell surface
interaction for virus entry. Sera derived from chimpanzees
immunized with homologous HCV glycoproteins neutral-
ized E1 or E2 pseudotype virus infectivity (Lagging et al.,
1998). We also used the pseudotype virus as a surrogate
model in determining virus neutralization activity of HCV-
infected patient sera. Pseudotype virus neutralizing activity
of patient sera did not exhibit a correlation with the genotype
of the infecting HCV, suggesting that neutralizing epitope(s)
may be shared among HCV genotypes (Lagging et al.,
2002). Only a limited number of studies have been directed
to mutation(s) of the glycosylation sites to determine which
specific N-linked glycans are critical for envelope protein
function. We extended our investigation in determining
whether E1-G glycoprotein processing is affected as a result
of translocation from the ER to the cell surface, and how the
carbohydrate portion on E1-G influences its functional
properties.Results
Transport of E1-G chimeric glycoprotein to mammalian cell
surface and Endoglycosidase H sensitivity
HCV E1 glycoprotein contains an ER retention signal in
its transmembrane (TM) domain. The removal of the ER
retention sequence allows secretion of E1 as a recombinant
protein in mammalian cell culture medium. We generated a
chimeric E1 glycoprotein construct (E1-G) by replacing its
TM domain with sequences encoding VSV G TM domain
and cytoplasmic tail for translocation of E1 on cell surface
(Lagging et al., 1998). Confocal microscopy using a mono-
clonal antibody to E1 glycoprotein (A4), anti-calnexin
antibody as an ER marker, or anti-giantin antibody as a
Golgi marker suggested that chimeric E1-G does transit
from the ER through the Golgi complex (Fig. 1, panel A).
To determine whether the oligosaccharides present on E1-Gugh Golgi complex. HeLa cells were infected with recombinant vvT7 and
MAb A4 to E1 and rabbit anti-calnexin antibody as an ER marker or rabbit
conjugate and rabbit Ig-TRITC conjugate were used. Fluorescence images
Endo H sensitive. HeLa cells were infected with recombinant vvT7 and
3 vector as a negative control. After 18 h of transfection, cells were labeled
MAb A4 to E1 and left as untreated control or treated with Endo H. Samples
ft indicate positions of protein bands from undigested or Endo H digested
nvitrogen) are indicated as kilodaltons on the right. (Panel C) Western blot
combinant vvT7 and transfected with plasmid DNA encoding chimeric E1-
fection, cell lysates were immunoprecipitated with a MAb to E1 (Austral
as a control. Samples were analyzed by SDS-12% PAGE, transferred to
y anti-mouse immunoglobulin peroxidase conjugate. The peroxidase signal
protein bands from undigested or Endo H digested (marked by *) E1-G or
as kilodaltons on the right.
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surface, the chimeric glycoprotein was treated with Endo-
glycosidase H (Endo H), which catalyzes the hydrolysis of
N-linked oligomannose and hybrid, but not complex, oligo-
saccharides. The surface expressed chimeric E1-G displayed
Endo H sensitivity similar to ER resident full-length E1
glycoprotein (Fig. 1, panel B), suggesting additional com-plex sugars were not added to this chimeric E1-G. Molec-
ular weight of E1-G appeared as a major polypeptide of
approximately 34.5 kDa, and a minor band of approximately
31.5 kDa. Upon Endo H treatment, E1-G displayed a major
polypeptide band of approximately 21.0 kDa. On the other
hand, full-length E1 glycoprotein exhibited a protein band
of approximately 32.0 kDa and a relatively minor polypep-
Fig. 2. E1-G protein expression profile following mutation of the potential
glycosylation sites. HeLa cells were infected with recombinant vvT7 and
transfected with E1-G or its mutants at the glycosylation sites. After 18 h of
transfection, cells were labeled with 35S-cysteine/methionine for 2 h. Cell
lysates transfected with E1-G or its mutants (as indicated on top of each
lane) were immunoprecipitated with a murine MAb A4 to E1, and analyzed
by SDS-12% PAGE under reducing conditions. Similar analysis with the
empty vector control is also shown. The positions of protein molecular
weight markers (Invitrogen) are indicated as kilodaltons on the right.
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to an approximately 17.5-kDa band. The reduction in
molecular weight of the full-length E1 glycoprotein was in
agreement with the calculated size of E1-G chimeric con-
struct following Endo H treatment. Similar results were also
obtained by Western blot analysis from immunoprecipitated
E1-G, following Endo H digestion (Fig. 1C). These results
indicated that the glycosylation pattern of chimeric E1-G
was similar to the full-length E1 glycoprotein containing
high mannose oligosaccharides even after translocation
from the ER to mammalian cell surface via Golgi complex.
Role of glycosylation sites on protein expression profile of
E1-G
The E1 glycoprotein (approximately 32 kDa) consists of
191 amino acids encoding from amino acid positions 192 to
383 of the HCV genotype 1a polyprotein sequence. Most of
the HCV genotypes have five conserved potential N-glyco-
sylation sites in their E1 sequence (asparagine positions 196,
209, 234, 305, and 325). However, the site at position 325
(Asn-Trp-Ser-Pro) is not used for the addition of an N-linked
glycan. We asked how mutation of a single or multiple
glycosylation sites in the E1 sequence may affect molecular
size of the chimeric E1-G glycoprotein. To address this
question, we replaced the asparagine residues of 196, 209,
234, and 305 with glutamine by oligonucleotide-directed
mutagenesis to prevent the addition of N-linked oligosac-
charides. Mutations at each of the four amino acid positions
were verified by automated DNA sequence analysis. E1-G
glycosylation mutants were cloned under the control of a
cytomegalovirus early promoter into pcDNA3 mammalian
expression vector for transient protein expression in HeLa
cells. Analysis of protein expression from the mutated clones
were compared with the parental E1-G or vector control by
immunoprecipitation, and results suggested a consistent
decrease of molecular weight with single or multiple muta-
tions at the E1-G glycosylation sites (Fig. 2). The chimeric
E1-G glycoprotein appeared as an approximately 34.5-kDa
polypeptide band. On the other hand, mutation at a single
glycosylation site (N196!Q) displayed a major protein band
approximately 32 kDa and a minor polypeptide of approxi-
mately 29 kDa probably representing partially glycosylated
form of this protein. A similar change in molecular weight of
the polypeptide bandwas also observedwith singlemutations
at three other glycosylation sites (data not shown). The other
three additive mutants exhibited synthesis of distinct poly-
peptides of different molecular weights (approximately 29,
25, and 20 kDa) depending on the number of mutations
performed on N-glycosylation sites.
Role of glycosylation sites on transport of E1-G chimeric
glycoprotein
Transient expression of E1-G mutant glycoprotein on
HeLa cell surface was examined by immunofluorescencefrom unfixed cells. All of the E1-G mutated proteins were
recognized by a MAb targeting a linear epitope located
between aa 192 and 280 on the polyprotein or by MAb A4
recognizing a linear epitope between amino acids 197 and
207, which corresponds to a domain outside of the N-linked
glycosylation sites. Our results suggested a gradual decrease
in cell surface expression level of E1-G protein with an
increasing number of mutations to the glycosylation sites
(Fig. 3, panels A and B). Translocation of the mutated E1-G
to the cell surface was quantitated subsequently by FACS
analysis. Approximately 29% of cells displayed cell surface
expression of E1-G chimeric glycoprotein by FACS. Similar
analyses suggested approximately 12–20% cell surface
expression of E1-G following single mutation at any one
of the four glycosylation sites. On the other hand, double
mutations at two different amino acids, 196 and 305,
decreased E1-G surface expression to approximately 7.5%.
Cell surface expression of E1-G was almost undetectable
(approximately 3%) when three of the glycosylation sites
were mutated simultaneously. Mutations of all four glyco-
sylation sites failed to display any significant signal (ap-
proximately 1.5%) by FACS analysis.
To investigate intracellular localization of E1-G or its
mutants, we performed confocal microscopy. Permeabilized
cells were double stained with an E1 specific murine MAb
A4, and with a rabbit antibody to calnexin as an ER marker.
Fig. 3. Cell surface expression of E1-G and its mutants at the glycosylation sites. (Panel A) HeLa cells grown on coverslip were infected with vvT7 and
transfected with E1-G or its mutants at the glycosylation sites. Unfixed cells were treated with E1 specific MAb A4 and stained with FITC-conjugated anti-
mouse Ig. (Panel B) HeLa cells transiently transfected with E1-G or its mutants were treated with E1 specific MAb A4 (bold line) or isotype specific unrelated
MAb as a negative control (dotted line) and stained with FITC-conjugated anti-mouse Ig for FACS analysis. Mock-transfected cells were also treated separately
with E1 specific MAb A4 and FITC-conjugated anti-mouse Ig for comparison (thin line). The percentage of FITC-positive cells is indicated in each histogram.
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mouse Ig-FITC for detection of E1 glycoprotein and anti-
rabbit Ig-TRITC conjugate for detection of calnexin. Con-
focal microscopy suggested that E1 glycoprotein or its
single glycosylation site mutants are expressed primarily
on the cell surface as a clear green boundary above red-
stained ER (Fig. 4). Interestingly, E1 glycoprotein graduallydecreased its surface expression and localized in the ER
with an increasing number of mutations at the glycosylation
sites, as evident from the merge of green and red signals
from confocal microscopy. The unglycosylated E1-G pro-
tein was also double stained with E1 specific A4 monoclo-
nal antibody and with a rabbit antibody to giantin as a Golgi
marker, and confocal microscopy suggested that the ungly-
Fig. 4. Intracellular localization of E1-G or its mutants at glycosylation sites. HeLa cells were infected with recombinant vvT7 and transfected with E1-G or its
mutants (marked on the right). After 18 h of transfection, cells were permeabilized and treated with MAb A4 to E1 and a rabbit antibody to calnexin as an ER
marker. Fluorescence images of E1 expression (green) and ER staining (red) were merged digitally for fine comparison by confocal microscopy.
A. Beyene et al. / Virology 324 (2004) 273–285278cosylated E1-G mutant fails to translocate to the Golgi (data
not shown).
Mutation of E1-G glycosylation sites affects pseudotype
virus titer
We examined whether VSV pseudotype generated from
E1-G mutant retains infectivity. For this, pseudotype virus
was generated by infecting BHK cells stably expressing E1-
G or its N-linked glycosylation site mutants with VSVts045.
Pseudotype titer was determined from the clarified culture
supernatant in two different human epithelial cell lines
(Huh-7 and MCF7), and in BHK cells for comparison
(Fig. 5). Culture supernatant from pcDNA3 vector trans-
fected cells, infected with VSVts045, was included as anegative control. A higher pseudotype plaque titer with E1-
G was apparent in both Huh-7 and MCF7, as compared to
BHK cells. Pseudotypes generated from single or double
mutants displayed plaque titers in each of the cell lines.
Interestingly, virus plaque formation was reduced by ap-
proximately 5-fold upon mutation of E1-G at single glyco-
sylation site (amino acid residue 196, 209, or 234), which
may be due to a decrease in expression level of the mutant
E1-G on cell surface. On the other hand, approximately 2-
fold reduction of pseudotype titers were observed following
mutation of E1-G at amino acid residue 305, although the
protein expression level was less compared to the other
single mutations. This could be due to diminished function-
ality of E1-G for mutation at amino acid position 305.
Mutations at two different glycosylation sites (amino acids
Fig. 5. Comparison of pseudotype titers generated from E1-G or its mutants at N-linked glycosylation sites. Three different cell types (Huh-7, MCF7, and
BHK) were separately infected with pseudotype virus bearing E1-G or its mutants. Virus generated from pcDNA3 vector as a negative control was examined
similarly for plaque formation. Plaque assay was done at 32 jC and virus titers (pfu/ml) are presented as mean value together with a standard deviation from at
least three different experiments.
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approximately 8- to 10-fold. Mutations at three different
glycosylation sites (amino acid residues 196, 234, and 305)Fig. 6. N-glycosidase F treatment of pseudotype virus. Pseudotype generated fr
N-glycosidase F or left as untreated control for 24 h at 37 jC. Virus titer wa
presented as the mean value together with standard deviations from at least tof E1-G reduced virus titer by approximately 20-fold.
Culture supernatant from a mock-transfected negative con-
trol exhibited a weak or almost undetectable virus titer.om E1-G or its mutants and VSVts045 of known titer were treated with
s determined by plaque assay in Huh-7 cells at 32 jC. The results are
hree different experiments.
Table 1
Pseudotype virus neutralization by HCV-infected human sera
Seraa Untreated E1-G
pseudotype control
(% reduction)
N-glycosidase
F-treated E1-G
pseudotype
(% reduction)
Untreated
VSVts045 control
(% reduction)
A 51 64 <10
B 60 94 15
C 69 64 16
D 65 46 15
E 51 74 <10
F 66 65 19
G <10 <10 <10
H <10 <10 <10
a Coded HCV-positive human sera (A–F) and sera from healthy donors as a
negative control (G–H) were tested at 1:20 dilution for neutralization of
pseudotype virus and VSVts045 control.
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with a decrease in transport of E1-G on cell surface.
However, mutation at amino acid residue 305 did not
decrease virus titer to the same extent as observed with
the other three mutants and the reason for this remains
unclear at present.
N-glycosidase F treatment of pseudotype virus reduces
infectivity
To understand whether enzymatic removal of preformed
oligosaccharide side chains from the ectodomain of E1
protein would have an effect on infectivity, pseudotype
virus generated from chimeric E1-G or its mutants were
treated with N-glycosidase F. This enzyme treatment
releases N-linked oligosaccharides from glycoproteins by
hydrolyzing the glycosylated h-amide bond of an aspara-
gine side chain. Denaturation of glycoprotein with detergent
and heat before N-glycosidase F digestion increases the
deglycosylation rate considerably; however, native protein
can still be deglycosylated by increasing the incubation time
to 24 h. As our aim was to determine infectious virus titer,
pseudotypes (prior determined to contain 100 pfu in Huh-7
cells) were treated with N-glycosidase F in phosphate buffer,
pH 7.5, in the absence of detergent or heat denaturation. A
test protein, ribonuclease B, was included as a positive
control for similar treatment. This positive control protein
displayed >90% oligosaccharide digestion as determined by
SDS-PAGE, followed by Coomassie blue staining (data not
shown). E1-G pseudotype titer was reduced by approxi-
mately 35% upon treatment with N-glycosidase F, compared
to mock-treated control. Similar results were also obtained
even when pseudotype virus generated from single, double,
or triple glycosylation site mutated clones were treated with
N-glycosidase F (Fig. 6). On the other hand, treatment of
VSVts045 (as a negative control) with the enzyme did not
significantly alter virus titer. These results suggested that
removal of glycans present on mature E1-G reduced pseu-
dotype titer to some extent, but was not able to completely
inhibit virus infectivity.
HCV-infected human sera neutralize glycosidase-treated
E1-G pseudotype
HCV E1 envelope glycoprotein is one of the targets for
virus neutralizing antibodies. The ability of HCV to evade
the immune system has been associated in part with both the
variability of the envelope protein sequence and possibly by
masking epitopes by glycosylation. Six HCV-infected hu-
man sera, previously identified as positive for E1 pseudo-
type neutralization (Lagging et al., 2002), were tested at a
1:20 dilution for inhibition of infectivity of N-glycosidase F-
treated pseudotype virus (Table 1). Sera from healthy donors
at 1:20 dilution were also included as a negative control. All
of these sera were also tested against the core virus
(VSVts045) as a negative control. Three of these sera (A,B, and E) displayed an increase in plaque reduction, while
serum D displayed a lower reactivity with enzyme-treated
E1-G pseudotype virus. Two other sera (C and F) exhibited
similar titer with N-glycosidase F-treated or untreated virus.
On the other hand, sera from healthy donors (G and H) did
not exhibit a significant neutralizing activity with the
pseudotype virus or VSVts045 used as a negative control.
Thus, the carbohydrate portion of the E1 glycoprotein did
not appear to have a major significance in defining the
neutralizing epitope(s).Discussion
In this study, we have examined the role of glycans in the
maturation and transport of HCV E1-G chimeric glycopro-
tein on to the mammalian cell surface, its similarities to full-
length E1, and its incorporation into pseudotype virus
particles for the infectivity of mammalian cells. The oligo-
saccharide chains on the glycoproteins of many viruses play
an important role in promoting the appropriate disulfide
bond formation and folding that result in a fully functional
glycoprotein. Little is known in terms of the relative
contribution of the protein and carbohydrate to the various
activities of HCV envelope glycoproteins. The role of the
carbohydrate portion of E1 glycoprotein in other biological
or immunological functions, such as attachment to cell
surface, virus infectivity, and recognition by the host im-
mune system, is now being studied. We have shown that
both full-length E1 glycoprotein normally expressed in the
ER and surface expressed chimeric E1-G glycoprotein are
sensitive to Endo H treatment, indicating that the chimeric
E1-G contains a high mannose glycosylation pattern similar
to the full-length E1 glycoprotein. Translocation of E1-G
protein to the cell surface is decreased to a different extent
upon mutation of the number of glycosylation sites, and the
recovery of pseudotype virus generated from these mutants
also varies. N-glycosidase F treatment of the already syn-
thesized E1-G glycoprotein reconstituted on a VSVts045
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have shown that neutralization activity of patient sera is not
significantly altered upon treatment of the pseudotype virus
with N-glycosidase F. In the absence of a suitable cell
culture system for an efficient HCV replication, our work
highlights some of the interesting features of the E1 glyco-
protein. This work will serve as a prelude to detailed
investigations in determining the principal reactive group(s)
of the E1 glycoprotein, and how this relates to its complex
biological functions either alone or in association with E2 in
intact HCV particles.
Conformational changes of some proteins are in some
manner dependent upon glycosylation, whereas many pro-
teins do not display glycosylation dependence during fold-
ing (Helenius and Aebi, 2001). Additionally, glycans are not
usually essential for maintaining the overall folded structure
once a glycoprotein has folded (Helenius, 1994; Imperiali
and O’Connor, 1999; Olden et al., 1982). The biological
role of the oligosaccharides in N-linked glycoconjugates is
highly diverse. Carbohydrate markers are critical for intra-
cellular targeting and intercellular recognition phenomena.
Oligosaccharides on glycoproteins may play a role in
protecting polypeptides from proteolytic attack and influ-
encing the immunogenicity of the glycoproteins (Ellgaard et
al., 1999; Means and Desrosiers, 2000; Trombetta and
Helenius, 1998). Mutation of the glycosylation sites of
HCV E1 at amino acid positions 196, 209, and 234 does
not effect the antibody titer induced in mice, whereas
mutation at the fourth glycosylation site at position 305
significantly increases antibody response to E1 (Fournillier
et al., 2001). To investigate the antigenic determinants in
partially or fully unglycosylated E1-G protein, N-glycosi-
dase F-treated pseudotype virus was used for neutralization
by a group of selected HCV patient sera. Interestingly,
glycosidase treatment of pseudotype virus did not signifi-
cantly alter the neutralizing activity of these sera. These
results do not necessarily imply that carbohydrates play no
role whatsoever in determining the immunological proper-
ties of E1 glycoprotein. Antibodies in patient sera were
induced against fully glycosylated E1 glycoprotein during
natural infection, and although they appear to react with
nonglycosylated portions of the molecule, their specificity
probably depends on molecular conformation, which could
be influenced, at least to some degree, by the carbohydrate.
To examine the role played by N-linked carbohydrate
chains in functional activity, we set out to investigate whether
alterations in the glycosylation of E1-G would alter its
function. Our results suggest that a single or double glyco-
sylation mutation decreases the surface expression level as
compared to fully glycosylated E1-G. However, E1-G
expresses much less efficiently following mutations at three
of the four glycosylation sites, while mutations at all four
glycosylation sites lead to retention of the viral protein in the
ER. We have shown previously that the pseudotype virus
possibly enters into cells by receptor-mediated endocytosis,
as an inhibitor of vacuolar H+ ATPases interferes with virusinfectivity (Meyer et al., 2000). The transmembrane domain
of wild-type VSV G protein has been implicated for fusion
activity. Replacement of glycine residues at positions 16 and
18 in the transmembrane domain with either alanine or
leucine results in the complete loss of fusion activity (Clever-
ley and Lenard, 1998), while a single substitution at any of
these positions decreases activity by half. Because our
chimeric E1-G construct contains the G transmembrane
domain and cytoplasmic tail from VSV, we examined wheth-
er the TM domain contributes to infection of E1-G pseudo-
type by mutations at positions 16 and 18. Our results
indicated that these amino acid positions do not contribute
to E1-G pseudotype infectivity (data not shown), as observed
with VSV in context to its full-length G glycoprotein.
Information available from several other studies high-
lights the interesting features of HCV envelope glycopro-
teins. Recently, Bartosch et al. (2003a) presented data
suggesting that MuLV/E1 or E2 pseudotype have the ability
to independently infect cells, but to a much lower extent as
compared to E1/E2 together. The authors suggested that high
infectivity of the pseudotype particles required both E1 and
E2 HCV glycoproteins. Pseudotypes with lentivirus bearing
E1 and E2 have been shown to infect cells by other groups of
investigators (Drummer et al., 2003; Hsu et al., 2003). We
also have observed an approximately 4- to 8-fold higher
virus titer of VSV pseudotype generated from cell lines
stably expressing both E1-G and E2-G in comparison to
either of these two glycoproteins alone (unpublished obser-
vation). The transmembrane domains of E1 and E2 are
involved in heteromerization by noncovalent interactions
(Op De Beeck et al., 2000, 2001; Ralston et al., 1993).
However, we do not know at present whether this interaction
imparts an effect on the structural relationship between the
ectodomains of these two envelope proteins. It could be
possible that both E1 and E2 associate through their trans-
membrane domains, while their ectodomains retain the
ability to display independent functional activities. This is
relevant with regard to the following interesting observa-
tions: (i) a truncated soluble form of E1 binds to CD81 and is
conformation dependent (Flint et al., 1999), while others
have suggested that noncovalently linked E1E2 complex
recognizes CD81 (Cocquerel et al., 2003); (ii) murine
monoclonal antibodies that were characterized earlier as
recognizing conformation-dependent epitopes of the E2
glycoprotein (Deleersnyder et al., 1997) react with E2
chimeric protein (Basu et al., 2004; Flint et al., 1999; Forns
et al., 2000); (iii) a human MAb (CBH-2) has been charac-
terized as recognizing E2 more efficiently only when it is
complexed with E1 than E2 alone (Cocquerel et al., 2003;
Hadlock et al., 2000); (iv) we consistently obtain infectivity
from pseudotype virus bearing E1 or E2 as a single, chimeric
envelope component (Basu et al., 2004; Lagging et al., 1998;
Meyer et al., 2000, 2002); and (v) the human scavenger
receptor class B type 1 (SR-B1), implicated as a HCV
receptor, displays a strong affinity to E2 glycoprotein (Scar-
selli et al., 2002). However, HCV envelope (E1-E2)-derived
A. Beyene et al. / Virology 324 (2004) 273–285282lentivirus pseudotype particles were shown to require ex-
pression of CD81, LDL receptor, SR-B1, and liver-specific
unknown cofactor(s) for infection (Bartosch et al., 2003b).
Although physicochemical and binding properties of the
viral glycoproteins may not necessarily correlate with pseu-
dotype infectivity, all of these interesting observations raise
questions regarding the structural and functional differences
of the E1 and E2 glycoprotein molecules alone or in
association, and merit further investigation.
Taken together, we hypothesize that the heteromeric form
of the associated E1 and E2 glycoproteins has exposed
ectodomains through which they can display independent
functional activities. The increase in infectivity titer with
pseudotype bearing E1/E2 may be due to a synergistic effect
for recognition of multiple receptors present on mammalian
cells. Further studies are necessary for understanding the
relationship between the ectodomains of E1 and E2, and their
interplay with mammalian cells in facilitating virus entry.Materials and methods
Cell lines and plasmids
Human cervical carcinoma cells (HeLa), baby hamster
kidney cells (BHK-21), human breast cancer cells (MCF7),
and human hepatoma cells (Huh-7) were grown and main-
tained in Dulbecco’s medium supplemented with 10% fetal
calf serum and antibiotics (100 U/ml penicillin and 100 Ag/
ml streptomycin).
Generation of plasmid containing chimeric E1-G gene
under control of a cytomegalovirus (CMV) promoter has
been described earlier (Lagging et al., 1998). E1 has four
conserved potential glycosylation sites at amino acids posi-
tions 196, 209, 234, and 305. Site-direct mutagenesis at
these four glycosylation sites on E1-G was performed by
replacing asparagine with glutamine using a Quick Change
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA),
following manufacturer’s instruction. For each clone, sense
and anti-sense primers were designed with the nucleotide
change of the asparagine residues at the positions of interest
(Table 2). Cloned DNAs were verified for altered nucleo-
tides by automated sequencing (ABI prism).Table 2
Oligonucleotide primers used to mutate E1-G glycosylation sites
Mutation sites Prim
N196Q sense
antis
N209Q sense
antis
N234Q sense
antis
N305Q sense
antis
a Underlined nucleotides indicate the mutations introduced in the E1-G sequenceAntibodies
Mouse monoclonal antibody A4, recognizing a linear
epitope of E1 glycoprotein, was kindly provided by J.
Dubuisson (Institut Pasteur de Lille Cedex, France). A
different mouse monoclonal antibody recognizing linear
epitope of E1 glycoprotein (Austral Biologicals, San
Ramon, CA), rabbit antibodies to calnexin (Stressgen,
Canada) and giantin (Covance Inc., CA), an anti-mouse
immunoglobulin-FITC conjugate and anti-rabbit immuno-
globulin-TRITC conjugate (Molecular Probes, Eugene, OR)
were purchased.
Metabolic labeling and immunoprecipitation
HeLa cells were infected with a recombinant vaccinia
virus expressing T7 polymerase (vvT7) at a multiplicity of
infection (moi) of 2 and transfected with plasmid DNA
encoding full-length E1, chimeric E1-G or E1-G mutants.
Cells were metabolically labeled with 200 ACi/ml 35S-
cysteine/methionine protein labeling mix as described pre-
viously (Ray et al., 1994). Cells were lysed after 18 h of
transfection, and E1 was immunoprecipitated with either
MAb A4 or a commercially available MAb to E1 (Austral
Biologicals).
Endoglycosidase H digestion
Immunoprecipitated proteins were eluted from protein G-
Sepharose in 25 Al buffer (100 mM phosphate buffer, pH
5.5, 0.2% SDS, and 1% h-mercaptoethanol) by boiling for
10 min. Samples were digested with Endoglycosidase H
(Endo H; Calbiochem, La Jolla, CA) or left untreated as a
negative control for 24 h at 37 jC. Samples were mixed
with an equal volume of 2 sample reducing buffer.
Samples were analyzed by SDS-PAGE, followed by auto-
radiography.
Western blotting
HeLa cells were infected with vvT7 at a moi of 2 and
transfected with plasmid DNA encoding chimeric E1-G,
full-length E1, or pcDNA3 vector as a negative control.er sequencesa
primer: 5V-GCCTACCAAGTGCGCCAATCCACGGGGCTTTAC-3V
ense primer: 5V-GTAAAGCCCCGTGGATTGGCGCACTTGGTAGGC-3V
primer: 5V-CCAATGATTGCCCTCAATCGAGTATTGTGTAC-3V
ense primer: 5V-GTACACAATACTCGATTGAGGGCAATCATTGG-3V
primer: 5V-GCGTTCGTGAGGGCCAAGCCTCGAGGTGTTGG-3V
ense primer: 5V-CCAACACCTCGAGGCTTGGCCCTCACGAACGC-3V
primer: 5V-CGACGCAAGGTTGCCAATGCTCTATCTATCCC-3V
ense primer: 5V-GGGATAGATAGAGCATTGGCAACCTTGCGTCG-3V
to alter potential glycosylation sites.
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protein was immunoprecipitated using a specific murine
Mab (Austral Biologicals). Immunoprecipitates were
digested with Endo H or left untreated as a negative control
for 24 h at 37 jC. Samples were separated by SDS–12%
polyacrylamide gel electrophoresis, and the proteins were
transferred onto nitrocellulose membrane. HCV E1 protein
was detected with mouse MAb A4 and anti-mouse immu-
noglobulin conjugated to peroxidase. The peroxidase signal
was visualized by chemiluminescence.
N-glycosidase F treatment
Pseudotype virus generated from chimeric E1-G or its
mutants of known titer was treated with or without N-
glycosidase F (Calbiochem) as a control for 24 h at 37 jC
in phosphate buffer, pH 7.5, as recommended by the
manufacturer. Denaturation of glycoprotein with detergent
and heat before N-glycosidase F digestion increases the
deglycosylation rate considerably; however, native protein
can still be deglycosylated by increasing the incubation time
to 24 h. We also tested the efficacy of N-glycosidase F
treatment using ribonuclease B (protein containing high
mannose) as a positive control under similar experimental
conditions as pseudotype virus was treated. Comparison
between untreated and treated samples displayed >90%
oligosaccharide digestion of ribonuclease B, as determined
by densitometric scanning (SynGene Gel Documentation
System, UK) of Coomassie blue-stained gel.
Immunofluorescence and confocal microscopy
HeLa cells grown on coverslips were infected with vvT7
at a moi of 2 and transfected with plasmid DNA encoding
E1 glycoprotein using lipofectamine (Invitrogen, Carlsbad,
CA) following the manufacturer’s protocol. At 18 h post-
transfection, cells were left either unfixed or were fixed in
10% formaldehyde for 20 min at room temperature. Cells
were treated with anti-E1 MAb A4 and a rabbit antiserum to
calnexin as an ER marker or anti-giantin as a Golgi marker.
Secondary antibody conjugated to fluorochrome was added
subsequently. Cells on coverslips were fixed after staining
and mounted on microscope slides in antifade reagent
(Molecular Probes) for microscopy using a Zeiss Axiovert
135 or a BioRad 1024 confocal microscope.
Pseudotype generation using single or multiple mutations
on E1G glycosylation site
Incorporation of HCV E1-G chimeric glycoprotein into a
temperature-sensitive mutant of VSV (VSVts045) has been
previously described for understanding the functional prop-
erties of the ectodomain of HCV E1 glycoprotein (Meyer et
al., 2002). VSVts045 has a G protein with a single amino acid
change in the ectodomain and a thermoreversible folding
phenotype (Doms et al., 1993). At nonpermissive tempera-ture (40.5 jC), G protein of VSVts045 is synthesized and
core glycosylated normally, but does not fold correctly.
However, the temperature-sensitive mutant virus does not
tightly regulate this process and the possibility for leakage of
G cannot be ruled out. To safeguard this, we have used a
stock of VSVts045 selected after four rounds of plaque
purification, which did not exhibit any significant back-
ground virus leakage at 40.5 jC. The plaque purified
VSVts045 virus stock was used for the generation of VSV/
HCV pseudotype by infecting BHK stable transfectants
expressing E1-G or mutant protein. Cells transfected with
an empty vector were similarly treated with VSVts045 as a
negative control. Wild-type VSV G (VSV Gwt) cloned into
pcDNA3 under the control of a T7 promoter was also used as
a positive control for generation of pseudotype virus (Lag-
ging et al., 1998). The culture fluid was flash frozen in
aliquots, and each aliquot was thawed only once for use in
a single round of virus replication by plaque assay for
VSVts045 at a permissive temperature (32 jC). The pseudo-
type virus showed titers in the order of approximately 104
pfu/ml in BHK cells, while mock-transfected negative con-
trol displayed less than 1% of virus titer, and Gwt/VSV
displayed a titer of approximately 105 pfu/ml. Treatment of
pseudotype virus with an antiserum to VSV G did not
significantly alter virus titer, suggesting the absence of
revertant VSV G in the virus preparation. The pseudotype
virus from E1-G was neutralized by known HCV-infected
patient sera (Lagging et al., 2002), and none of these sera at
similar dilutions exhibited a significant neutralization titer
(<20%) for VSVts045 when tested as a negative control. Sera
from healthy adults also displayed neutralization titer of
(<10%) of E1-G or VSVts045 virus infectivity. These results
further suggested the versatility of parental VSVts045 for
recognition, and entry into mammalian cells, and the relative
constraints placed upon VSV pseudotype virus expressing
the E1-G glycoprotein. On the other hand, antibody to VSV-
G efficiently neutralized VSV-G pseudotype virus.
Neutralization assay of deglycosylated pseudotype virus by
HCV-infected human sera
Infectivity of the E1 pseudotype virus depends upon the
interaction of HCV glycoproteins with target cells (Lagging
et al., 1998). Once the VSVts045 genome enters after
interaction of E1 with the cell surface, normal replication
of VSVts045 occurs at permissive temperature (32 jC), and
virus plaques are detected. Pseudotype virus generated from
E1-G or its mutants of known titer was treated with N-
glycosidase F (Calbiochem) or left as untreated control for
24 h at 37 jC in phosphate buffer, pH 7.5. A plaque assay
for virus infectivity and its neutralization by antibodies were
determined in mammalian cells at 32 jC in a serum-free
medium (Meyer et al., 2000, 2002). Pseudotype virus of a
known titer was incubated with HCV-infected human sera or
sera from healthy donors as negative control at 32 jC for 1 h.
Cells incubated with virus–antibody mixture for 1 h with
A. Beyene et al. / Virology 324 (2004) 273–285284intermittent tilting. Cells were washed and overlaid with
0.8% agarose in DMEM, containing 2% fetal bovine
serum. Virus plaques were read after 24–48 h of incuba-
tion at 32 jC in a 5% CO2 incubator.Acknowledgments
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